VIR-3434 Antibody Tested in Chronic Hepatitis B Infection

Trial details

Who runs it

University Health Network, Toronto

Trial code

NCT06216470

Record updated

29 May 2025

Original description

This is a Phase II Investigator-Initiated Study to understand the vaccinal effect of HBsAg monoclonal Ab VIR-3434 in chronic hepatitis B infection.Read full original descriptionShow less

Phase II Investigator-Initiated Study to Understand the Vaccinal Effect of HBsAg Monoclonal Ab VIR-3434 in Chronic Hepatitis B Infection

This is a Phase II Investigator-Initiated Study to understand the vaccinal effect of HBsAg monoclonal Ab VIR-3434 in chronic hepatitis B infection.

The purpose of this study is to test VIR-3434, an experimental drug that specifically targets the HBsAg of hepatitis B virus, to clear it from the body.

This is an open label study and there is no placebo used in this study. All participants will receive the VIR-3434 for 48 weeks and then follow up in the study for 48 weeks. A total duration of approximately 104 weeks including screening period for the entire study.

Inclusion: Age ≥ 18 to ≤65 years; Chronic HBV infection with evidence of HBsAg-positivity x > 6 months; Quantitative HBsAg 300 - 10,000 IU/mL; On stable nucleos(t)ide therapy >1 year; HBV DNA < 60 IU/mL on 2 occasions at least 12 weeks apart; ALT ≤ 45 U/L on 2 occasions at least 12 weeks apart; Female subjects must have a negative pregnancy test or confirmation of postmenopausal status. Women of child-bearing potential (WOCBP) must have a negative pregnancy test at screening and on Day 1, cannot be breast feeding, and must be willing to use highly effective methods of contraception 14 days before study drug administration through the study participation. Female subjects must also agree to refrain from egg donation and in vitro fertilization from the time of study drug administration through the study participation; Male subjects with female partners of child-bearing potential must agree to meet 1 of the following contraception requirements from the time of study drug administration through the study participation: documentation of vasectomy or azoospermia, or male condom use plus partner use of 1 of the contraceptive options listed for contraception for WOCBP. Male subjects must also agree to not donate sperm from the time of study drug administration through the study participation; Able and willing to sign informed consent.

Exclusion: History of cirrhosis as evidenced by prior Liver Elastography (Fibroscan) > 12 kilopascals (kPa), liver biopsy (F4 by METAVIR) or clinical evidence of decompensation (ascites, hepatic encephalopathy); Use of chronic immunosuppressive medications at a dose equivalent to 10 mg daily of prednisone or greater within past 6 months; Other significant medical illness that might interfere with this study: significant pulmonary dysfunction in previous 6 months, malignancy other than non-melanoma skin cancer in previous 5 years, immunodeficiency syndrome; Subject has received any investigational drug (including any investigational vaccines) within 90 days or 5 half-lives (whatever is longer) before screening for this study or is currently enrolled in an investigational study; Prior liver or other solid organ transplantation; History of or current hepatocellular carcinoma; Hepatitis C Virus (HCV) RNA or anti-Hepatitis D Virus (HDV) positive; HIV co-infection; History of chronic liver disease other than HBV aside from fatty liver documented only on US; Use of peginterferon therapy for HBV infection within past 12 months; Subject has any condition for which, in the opinion of the investigator, participation would not be in the best interest of the subject (eg, compromise the well-being) or that could prevent, limit, or confound the protocol-specified assessments, such as liver FNAs; Patients on anticoagulation therapy or with any bleeding diathesis; Patients with hemoglobinopathy (thalassemia, sickle cell disease etc); Other significant liver disease: alcoholic liver disease, autoimmune hepatitis, hemochromatosis, primary biliary cholangitis, primary sclerosing cholangitis, Wilson Disease or alpha-1 antitrypsin deficiency - as documented in clinical history; Alanine Aminotransferase (ALT) > 45 U/L; Platelet count < 120,000,000,000/L; The International Normalised Ratio (INR) > 1.3; Bilirubin > 40 µmol/L; Hemoglobin < 110 g/dL for women or 120 g/dL for men; estimated Glomerular Filtration Rate (eGFR) < 45 cc/min; Pregnancy or lactation; Alpha Fetoprotein (AFP) > 50 ng/mL; Unable to provide informed consent.

ClinicalTrials.gov NCT06216470